patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_951942 | REC_0009201 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15 | 68 | male | 0 | 14 | 7.1 | 1 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:35:59.125432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416484 | REC_0009202 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15.3 | 84 | female | 2 | 12 | 7.3 | 6 | alectinib 600 mg BID | 9.2 | true | MSI-H | 2026-03-15T05:35:59.125677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314795 | REC_0009203 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13.8 | 74 | male | 2 | 18 | 8.1 | 2 | entrectinib 600 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:35:59.125927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503791 | REC_0009204 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 14.4 | 77 | female | 0 | 6 | 5.2 | 8 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:59.126194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690368 | REC_0009205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.4 | 70 | female | 1 | 15 | 4.8 | 8 | alectinib 600 mg BID | 7.4 | false | MSS | 2026-03-15T05:35:59.126537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294946 | REC_0009206 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.7 | 58 | female | 0 | 16 | 4.7 | 3 | pembrolizumab 200 mg q3w | 19.6 | true | MSS | 2026-03-15T05:35:59.126801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577804 | REC_0009207 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.8 | 79 | female | 3 | 36 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.127043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751404 | REC_0009208 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 14.3 | 66 | male | 1 | 4 | 4.1 | 8 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.127280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593611 | REC_0009209 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 15.4 | 57 | male | 0 | 16 | 7.8 | 1 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.127517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638418 | REC_0009210 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.9 | 80 | female | 2 | 16 | 5.6 | 7 | sotorasib 960 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:59.127761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376196 | REC_0009211 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 12.1 | 72 | female | 2 | 16 | 6.8 | 1 | sotorasib 960 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:59.128007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403242 | REC_0009212 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 16.3 | 70 | female | 1 | 9 | 5 | 6 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:59.128383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911147 | REC_0009213 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.7 | 72 | female | 1 | 15 | 6.4 | 6 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.128638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534851 | REC_0009214 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.2 | 73 | female | 1 | 21 | 4.3 | 2 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:59.128879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241130 | REC_0009215 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.4 | 59 | female | 1 | 66 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:59.129123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604819 | REC_0009216 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 11.7 | 75 | female | 1 | 8 | 5.5 | 6 | sotorasib 960 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:35:59.129363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225387 | REC_0009217 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 17 | 8 | 66 | female | 0 | 13 | 4.4 | 2 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:59.129600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811954 | REC_0009218 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5 | 84 | female | 1 | 26 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.2 | false | MSS | 2026-03-15T05:35:59.129909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970936 | REC_0009219 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 14.5 | 75 | male | 2 | 22 | 7.4 | 1 | sotorasib 960 mg daily | 20.2 | false | MSS | 2026-03-15T05:35:59.130153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278840 | REC_0009220 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 7.1 | 76 | female | 1 | 14 | 4.3 | 2 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:59.130384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483596 | REC_0009221 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.4 | 58 | female | 1 | 12 | 4.6 | 2 | sotorasib 960 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:59.130623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490664 | REC_0009222 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 9.7 | 75 | female | 3 | 11 | 5.2 | 5 | alectinib 600 mg BID | 6.4 | false | MSS | 2026-03-15T05:35:59.130857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295817 | REC_0009223 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.8 | 76 | female | 1 | 15 | 4.8 | 7 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:35:59.131090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783759 | REC_0009224 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 12.6 | 60 | male | 0 | 28 | 3.8 | 4 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:59.131328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695382 | REC_0009225 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 11.7 | 75 | male | 1 | 15 | 4.2 | 0 | entrectinib 600 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:59.131569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948382 | REC_0009226 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.8 | 70 | female | 0 | 13 | 5.6 | 5 | sotorasib 960 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:59.131814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117330 | REC_0009227 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 6.7 | 56 | male | 1 | 21 | 5.3 | 6 | sotorasib 960 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:59.132055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649932 | REC_0009228 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.5 | 63 | female | 1 | 16 | 5.4 | 6 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:59.132338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630576 | REC_0009229 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.3 | 74 | male | 3 | 13 | 7.7 | 7 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:59.132588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747995 | REC_0009230 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 9.5 | 57 | female | 0 | 11 | 5.6 | 5 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:59.132831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574435 | REC_0009231 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.1 | 68 | female | 0 | 5 | 7.3 | 7 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:35:59.133183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588289 | REC_0009232 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.6 | 72 | female | 3 | 18 | 4.7 | 6 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:59.133442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469863 | REC_0009233 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.4 | 58 | male | 1 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:59.133705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915747 | REC_0009234 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.4 | 63 | female | 0 | 22 | 7.3 | 4 | alectinib 600 mg BID | 15.6 | false | MSI-H | 2026-03-15T05:35:59.133968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290419 | REC_0009235 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.6 | 75 | female | 1 | 51 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:35:59.134226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828248 | REC_0009236 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.1 | 75 | female | 2 | 31 | 6.6 | 3 | pembrolizumab 200 mg q3w | 5 | true | MSS | 2026-03-15T05:35:59.134484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124761 | REC_0009237 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 3.7 | 71 | female | 2 | 23 | 6.2 | 7 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:35:59.134734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180798 | REC_0009238 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 15.4 | 85 | female | 2 | 22 | 4.3 | 2 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:35:59.134978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433677 | REC_0009239 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12 | 49 | male | 0 | 16 | 6 | 1 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.135240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731444 | REC_0009240 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.1 | 82 | female | 2 | 9 | 3 | 2 | osimertinib 80 mg daily | 24.4 | true | MSS | 2026-03-15T05:35:59.135484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672994 | REC_0009241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 18 | 69 | female | 0 | 3 | 3.5 | 6 | osimertinib 80 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:35:59.135728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252849 | REC_0009242 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 15.2 | 52 | female | 0 | 7 | 7.9 | 1 | entrectinib 600 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:59.135972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276850 | REC_0009243 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 3.5 | 86 | female | 1 | 18 | 7.6 | 2 | pembrolizumab 200 mg q3w | 9.9 | false | MSS | 2026-03-15T05:35:59.136258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655852 | REC_0009244 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 6.4 | 73 | female | 1 | 14 | 7.3 | 1 | entrectinib 600 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:59.136616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495088 | REC_0009245 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 12 | 67 | male | 1 | 14 | 5 | 7 | alectinib 600 mg BID | 5.5 | true | MSS | 2026-03-15T05:35:59.136881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328358 | REC_0009246 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 7.7 | 62 | female | 0 | 54 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:59.137127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679793 | REC_0009247 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.3 | 78 | female | 3 | 12 | 4.1 | 2 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:59.137374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988459 | REC_0009248 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9 | 74 | female | 0 | 18 | 6.7 | 2 | osimertinib 80 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:59.137627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584333 | REC_0009249 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 15.2 | 79 | female | 1 | 14 | 4.3 | 3 | pembrolizumab 200 mg q3w | 22.8 | false | MSS | 2026-03-15T05:35:59.137873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500039 | REC_0009250 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13.3 | 62 | female | 1 | 15 | 4.2 | 5 | entrectinib 600 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:35:59.138116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759427 | REC_0009251 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.3 | 84 | female | 2 | 52 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:35:59.138358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139124 | REC_0009252 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 13.2 | 61 | male | 1 | 22 | 3.3 | 1 | sotorasib 960 mg daily | 21 | true | MSI-H | 2026-03-15T05:35:59.138596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875343 | REC_0009253 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 7.5 | 64 | male | 1 | 22 | 4.9 | 4 | alectinib 600 mg BID | 13.8 | true | MSS | 2026-03-15T05:35:59.138830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315887 | REC_0009254 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.4 | 72 | female | 1 | 12 | 5 | 5 | pembrolizumab 200 mg q3w | 6 | false | MSI-H | 2026-03-15T05:35:59.139061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164588 | REC_0009255 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 16.6 | 47 | male | 0 | 23 | 6.5 | 1 | entrectinib 600 mg daily | 27.8 | false | MSI-H | 2026-03-15T05:35:59.139295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699344 | REC_0009256 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 2.7 | 67 | female | 1 | 33 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:59.139523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633401 | REC_0009257 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.6 | 52 | male | 0 | 5 | 5 | 3 | entrectinib 600 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:59.139845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392719 | REC_0009258 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.8 | 54 | female | 0 | 27 | 4.8 | 2 | osimertinib 80 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:59.140158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705256 | REC_0009259 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.8 | 69 | female | 1 | 30 | 5.2 | 1 | osimertinib 80 mg daily | 18.3 | true | MSI-H | 2026-03-15T05:35:59.140415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816079 | REC_0009260 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 11.3 | 64 | male | 0 | 15 | 4 | 5 | sotorasib 960 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:59.140660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490002 | REC_0009261 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 7.7 | 54 | female | 0 | 10 | 2.6 | 5 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:59.140901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665776 | REC_0009262 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 14.1 | 74 | female | 2 | 4 | 7.9 | 1 | alectinib 600 mg BID | 16.8 | false | MSS | 2026-03-15T05:35:59.141140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851780 | REC_0009263 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.9 | 59 | female | 0 | 59 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:35:59.141383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953397 | REC_0009264 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.2 | 76 | male | 3 | 25 | 5.6 | 4 | osimertinib 80 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:59.141622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738599 | REC_0009265 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 10.9 | 63 | male | 0 | 9 | 5.1 | 7 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:59.141856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937686 | REC_0009266 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.1 | 71 | female | 0 | 49 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:35:59.142089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634661 | REC_0009267 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 12.3 | 67 | female | 1 | 14 | 4.5 | 2 | sotorasib 960 mg daily | 24.5 | false | MSS | 2026-03-15T05:35:59.142324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972991 | REC_0009268 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 13.7 | 60 | male | 0 | 13 | 4.2 | 2 | sotorasib 960 mg daily | 21.3 | false | MSI-H | 2026-03-15T05:35:59.142565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590385 | REC_0009269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 16.5 | 70 | male | 2 | 12 | 7.5 | 7 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:35:59.142801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242176 | REC_0009270 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 12 | 57 | male | 1 | 12 | 6 | 5 | osimertinib 80 mg daily | 5.3 | true | MSS | 2026-03-15T05:35:59.143086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308688 | REC_0009271 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.5 | 65 | female | 1 | 16 | 5.5 | 5 | entrectinib 600 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:59.143324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607864 | REC_0009272 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 14 | 51 | male | 0 | 18 | 6 | 6 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:59.143560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319516 | REC_0009273 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.3 | 67 | male | 0 | 17 | 4.5 | 4 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.143797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344920 | REC_0009274 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.4 | 78 | male | 2 | 15 | 4.5 | 2 | alectinib 600 mg BID | 23.3 | false | MSS | 2026-03-15T05:35:59.144031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634929 | REC_0009275 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 3.7 | 78 | female | 1 | 11 | 6.2 | 5 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:59.144291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337188 | REC_0009276 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 4.3 | 66 | female | 1 | 18 | 4.5 | 5 | sotorasib 960 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:59.144520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392970 | REC_0009277 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 12.3 | 76 | female | 1 | 17 | 6.1 | 1 | entrectinib 600 mg daily | 34.4 | true | MSS | 2026-03-15T05:35:59.144754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873431 | REC_0009278 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.1 | 73 | female | 1 | 22 | 5.7 | 1 | osimertinib 80 mg daily | 9 | true | MSI-H | 2026-03-15T05:35:59.144985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207968 | REC_0009279 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.1 | 76 | female | 1 | 20 | 5 | 9 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:59.145217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812418 | REC_0009280 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 1.5 | 63 | female | 1 | 64 | 4.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:35:59.145445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872686 | REC_0009281 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.6 | 70 | female | 2 | 19 | 5.9 | 2 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.145682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238243 | REC_0009282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 12.8 | 66 | female | 1 | 11 | 5.7 | 5 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.145921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165938 | REC_0009283 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 13.2 | 82 | female | 1 | 22 | 6.3 | 2 | entrectinib 600 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:35:59.146212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613414 | REC_0009284 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.6 | 74 | male | 1 | 20 | 7.5 | 3 | pembrolizumab 200 mg q3w | 13.4 | true | MSS | 2026-03-15T05:35:59.146454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422113 | REC_0009285 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 12.2 | 61 | male | 1 | 29 | 5.2 | 2 | osimertinib 80 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:59.146702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969259 | REC_0009286 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 17.1 | 73 | female | 0 | 21 | 5.5 | 5 | entrectinib 600 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:59.146942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341408 | REC_0009287 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 8.3 | 79 | male | 3 | 16 | 6.4 | 4 | alectinib 600 mg BID | 4.6 | true | MSS | 2026-03-15T05:35:59.147184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823096 | REC_0009288 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.2 | 73 | female | 1 | 16 | 5.1 | 5 | sotorasib 960 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:59.147428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903703 | REC_0009289 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.5 | 59 | female | 1 | 18 | 4.9 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.147680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855994 | REC_0009290 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 2.4 | 63 | male | 0 | 15 | 6.3 | 1 | pembrolizumab 200 mg q3w | 22.5 | false | MSS | 2026-03-15T05:35:59.147928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261501 | REC_0009291 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 10 | 70 | female | 2 | 22 | 6.5 | 8 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:35:59.148239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310320 | REC_0009292 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 13.2 | 76 | male | 2 | 20 | 6.3 | 4 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:59.148508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468306 | REC_0009293 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.7 | 71 | female | 2 | 54 | 5.5 | 9 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:59.148752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996710 | REC_0009294 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 39 | 11.1 | 62 | male | 1 | 24 | 5 | 1 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.149005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558134 | REC_0009295 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.4 | 65 | female | 0 | 9 | 5.2 | 5 | entrectinib 600 mg daily | 10 | false | MSS | 2026-03-15T05:35:59.149254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981381 | REC_0009296 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 10.6 | 81 | male | 2 | 28 | 5 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.149603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465936 | REC_0009297 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 4.9 | 78 | female | 2 | 21 | 6.1 | 1 | pembrolizumab 200 mg q3w | 17.8 | true | MSS | 2026-03-15T05:35:59.149851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720505 | REC_0009298 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 2.6 | 63 | male | 0 | 2 | 5.6 | 2 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:59.150094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870045 | REC_0009299 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.6 | 71 | female | 1 | 19 | 6.2 | 4 | entrectinib 600 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:35:59.150339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501223 | REC_0009300 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 10.1 | 78 | female | 1 | 13 | 5.1 | 6 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:59.150581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.